|
|
|
|
|
|
|
|
|
The evidence gap in Hematology: From trial endpoints to patient outcomes
|
As hematology trials become more complex, sponsors face increasing pressure to accelerate development while generating stronger evidence, mitigating recruitment risk and supporting faster patient access. Join Parexel's experts to discover how RWD/RWE can help you make smarter decisions earlier, mitigate risk and strengthen your path from development to approval. Don't miss this opportunity — register today.
|
|
|
|
|
|
|
|
By Erin Harris, editor-in-chief, Cell & Gene
|
REVTORPYK's FDA approval highlights the broader push toward precision therapies that address complex disease biology, overcome resistance, and deliver more durable patient benefit.
|
|
|
|
|
|
|
|
|
|
|
|
Overcoming High Drop-Out Rates With Decentralized Trial Design
|
|
Article | MRN - Medical Research Network
|
High drop-out rates threaten clinical trial integrity. Implementing decentralized solutions and proactive support strategies during protocol design can significantly improve patient enrollment and retention.
|
|
|
|
CLINICAL TRIALS SOLUTIONS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
|
